| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Atherosclerosis and Lipoproteins |
From the Medizinische Klinik III (F.B., J.K., M.P., S.S., H.K., E.B.) and Medizinische Klinik I (B.I.), Universität Heidelberg, Heidelberg, Germany; and the Department of Pathobiology and Nutritional Science (M.E.R.), University of Washington, Seattle.
Correspondence to Erwin Blessing, MD, Medizinische Klinik III, Universität Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. E-mail erwin_blessing{at}med.uni-heidelberg.de
Objective Inflammatory mechanisms are involved in atherosclerotic plaque rupture and subsequent thrombin formation. Thrombin not only plays a central role in thrombus formation and platelet activation, but also in the induction of inflammatory processes. We assessed the hypothesis that melagatran, a direct thrombin inhibitor, attenuates plaque progression and promotes stability of advanced atherosclerotic lesions.
Methods and Results Melagatran (500 µmol/kg/d) or control diet was administered to apolipoprotein Edeficient mice (n=54) with advanced atherosclerotic lesions. Treatment reduced lesion progression in brachiocephalic arteries (P<0.005). Morphometric analysis confirmed that thrombin inhibition promoted plaque stability and resulted in thicker fibrous caps (28.4±14.2 µm versus 20.8±12.0 µm; P<0.05), increased media thickness (29.3±9.6 µm versus 24.4±6.7 µm; P<0.05), and smaller necrotic cores (73 537±41301 µm2 versus 126 819±51730 µm2; P<0.0005). Electro mobility shift assays revealed reduced binding activity of nuclear factor
B (P<0.05) and activator protein-1 (P<0.05) in aortas of treated mice. Furthermore, immunohistochemistry demonstrated reduced staining for matrix metalloproteinase (MMP)-9 (P<0.05). Melagatran had no significant effect on early lesion formation in C57BL/6J mice.
Conclusions The direct thrombin inhibitor melagatran reduces lesion size and may promote plaque stability in apolipoprotein Edeficient mice, possibly through reduced activation of proinflammatory transcription factors and reduced synthesis of MMP-9.
Effects of chronic thrombin inhibition with melagatran was evaluated in advanced lesions of apoE-deficient mice. Melagatran attenuated lesion progression and promoted plaque stability, possibly through inhibiting activation of proinflammatory transcription factors and reduced synthesis of MMP-9.
Key Words: direct thrombin inhibitor atherosclerosis plaque inflammation transcription factors MMP-9
This article has been cited by other articles:
![]() |
J. I. Borissoff, H. M.H. Spronk, S. Heeneman, and H. ten Cate Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovasc Res, June 1, 2009; 82(3): 392 - 403. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Li, T. Syrovets, S. Paskas, Y. Laumonnier, and T. Simmet Mature Dendritic Cells Express Functional Thrombin Receptors Triggering Chemotaxis and CCL18/Pulmonary and Activation-Regulated Chemokine Induction J. Immunol., July 15, 2008; 181(2): 1215 - 1223. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Popovic, Y. Laumonnier, L. Burysek, T. Syrovets, and T. Simmet Thrombin-induced expression of endothelial CX3CL1 potentiates monocyte CCL2 production and transendothelial migration J. Leukoc. Biol., July 1, 2008; 84(1): 215 - 223. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |